Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

27.83
+0.09000.32%
Post-market: 27.75-0.0798-0.29%19:34 EDT
Volume:1.17M
Turnover:32.71M
Market Cap:4.80B
PE:12.68
High:28.24
Open:27.98
Low:27.74
Close:27.74
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.80
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.67
PE(LYR):12.10

Loading ...

BRIEF-Acadia Pharmaceuticals Q1 EPS USD 0.02

Reuters
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Recent Returns Send Mixed Signals

Simply Wall St.
·
May 02

Acadia R&D chief Elizabeth Thompson to retire, company launches successor search

Reuters
·
May 01

ACADIA Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.z. Thompson, Ph.d., Head of Research and Development, Following a Distinguished Career

THOMSON REUTERS
·
May 01

Earning Preview: ACADIA Pharmaceuticals this quarter’s revenue is expected to increase by 17.56%, and institutional views are bullish

Earnings Agent
·
Apr 30

Acadia Pharmaceuticals announces virtual annual shareholder meeting

Reuters
·
Apr 29

ACADIA Pharmaceuticals publishes 2025 annual report

Reuters
·
Apr 29

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 28

Acadia presents Phase 4 LOTUS real-world DAYBUE data in Rett syndrome at AAN 2026

Reuters
·
Apr 17

Bank of America Securities Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 16

Acadia Pharmaceuticals to report first-quarter results after US market close

Reuters
·
Apr 16

Did DAYBUE STIX’s Flexible Rett Formulation Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

Simply Wall St.
·
Apr 16

A Look At Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX US Launch

Simply Wall St.
·
Apr 11

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 09

Acadia Pharmaceuticals announces Daybue Stix available in U.S.

TIPRANKS
·
Apr 07

ACADIA Pharmaceuticals Announces Daybue® Stix (Trofinetide) Is NOW Broadly Available in the United States for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Apr 07

RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

ACADIA Pharmaceuticals Shares Rise After BofA Upgrade

MT Newswires Live
·
Mar 26

BofA Securities Upgrades ACADIA Pharmaceuticals to Buy From Neutral, Price Target is $29

MT Newswires Live
·
Mar 25